Photo credits
.jpg){kind=link}
Why Phenelzine Still Matters
Phenelzine is one of the most effective antidepressants ever brought to market, and almost no one prescribes it. Fewer than 2% of psychiatrists write MAOIs with any regularity, and a whole generation of clinicians has trained and gone into practice without ever starting a single patient on one. The drug did not lose on the evidence. It lost on marketing, then on familiarity, and its reputation for danger has now far outrun how it behaves in careful hands.
That is a loss for patients. Phenelzine is a first-rate option for two hard populations that modern algorithms serve poorly: atypical depression (hypersomnia, hyperphagia, leaden paralysis, rejection sensitivity) and treatment-resistant depression that has already failed SSRIs, SNRIs, and augmentation. With its cousin tranylcypromine, it is also one of the most effective pharmacologic treatments for social anxiety disorder ever studied: a large effect size across five randomized trials, far beyond what the SSRIs deliver. When a patient has cycled through four or five agents without relief, "have they ever had an adequate MAOI trial?" is one of the highest-yield questions you can ask, and the answer is almost always no.
Phenelzine is safe and highly effective if you respect the two interactions that can hurt people (tyramine and serotonin), educate the patient thoroughly, push the dose to a fully therapeutic level, and manage orthostasis and the other nuisance side effects before they become a problem. The dietary and drug restrictions that frighten prescribers are real, but the list is finite, far shorter than the folklore suggests, and entirely teachable. A subset of your most treatment-refractory patients will then get a response no other class has given them.
Prescribers avoid phenelzine because it is unfamiliar, not because it is dangerous, and unfamiliarity feels like danger. The interactions are finite and the rules can be learned. After decades of use, the expert consensus is that catastrophic events are rare in educated patients. What looks like a minefield from a distance is a short checklist up close.
How to Use Phenelzine With Confidence
The hesitation is nearly universal. Clinicians avoid MAOIs because of three fears: the patient will eat the wrong cheese and stroke out; the patient will get a serotonergic drug from another provider and develop serotonin syndrome; and something will go wrong and it will feel like it was the prescriber's fault for using an "old, dangerous" drug. Each of these fears can be handled with a system, and this section lays one out.
Where the Risk Comes From
Phenelzine's risks are almost entirely interaction risks, not intrinsic toxicity. Unlike lithium, it has no narrow serum window to chase and no organ that silently fails on you. At a therapeutic dose the drug itself is well tolerated by most patients. What can hurt them is something they add: a food, an OTC decongestant, a triptan, a second antidepressant prescribed by a clinician who didn't know. So safety depends overwhelmingly on education and communication, not on laboratory vigilance.
The fix is to make the patient an informed co-manager of their own interaction risk and to make sure every other clinician who treats them knows they are on an MAOI.
The Patient Partnership: Build It on Day One
The single most protective thing you do is the conversation you have when you start the drug. Put it in writing, not just verbally: a clear, current handout that won't frighten the patient, covering:
The foods to avoid. The list is short (see the interactions section). It covers aged/fermented foods, not "all cheese and all wine."
The OTC products to avoid (decongestants, dextromethorphan-containing cough syrups, certain supplements) and the safe alternatives.
The rule for every new prescription: "Before any doctor, dentist, or pharmacist gives you anything new, prescription or over-the-counter, tell them you take an MAOI and have them check it with me."
The warning sign: a sudden, severe, pounding headache (patients classically describe a feeling that the head will "split"), especially with a racing heart, sweating, or nausea, plus what to do about it: how to reach you, when to go to the ER.
Some prescribers used to hand the patient a single 10 mg immediate-release nifedipine tablet to carry and chew if a splitting headache developed. That practice has been retired: chewed or sublingual nifedipine can drop blood pressure uncontrollably, and current MAOI guidance calls it strongly contraindicated (see the emergency section below). What the habit did well was psychological, because it turned a vague dread into a concrete plan, and patients who feel in control tolerate the medication better. Give the patient that sense of control with a written action plan they can recite, and leave the prohibitions as a list on the same page.
The MedicAlert Habit
Have the patient wear or carry MAOI identification (a MedicAlert bracelet or a card in their wallet). It protects against the scenario you can't prevent yourself: an emergency in which the patient can't speak for themselves and a treating clinician reaches for meperidine, a serotonergic agent, or a sympathomimetic. It costs almost nothing and closes the most dangerous gap in the whole system.
Push the Dose
The mistake that makes phenelzine "not work" is stopping at 45 mg because you're nervous. Early trials that used low doses failed to separate from placebo, and that failure helped tar the drug's reputation. The response threshold sits near 1 mg/kg, roughly 60–90 mg/day for most adults. Below it you often get side effects without benefit. If you're going to take on the interaction management, you owe the patient a therapeutic dose, and a trial that never reached one doesn't count as a failed MAOI trial.
Addressing the Specific Fears
The modern tyramine list is short, and reactions in educated patients are uncommon. One senior clinician (Dr. Jonathan Cole) recounted more than three decades of MAOI prescribing at McLean Hospital with practically one serious hypertensive event, and that one was a patient who took a massive overdose of pseudoephedrine, not someone who ate the wrong meal. Teach the list and give the written handout, and the risk becomes small.
Respect this interaction most, because it can be lethal and because it can come from a well-meaning outside prescriber. You defend against it with thorough patient education, MAOI identification, an explicit "clear every new drug with me" rule, and your own discipline about washout periods when starting or stopping. Know the serotonin rule cold (below) and the risk is manageable.
Old is not the same as worse: phenelzine has decades of efficacy data in exactly the populations where newer agents underperform. Document a thoughtful risk/benefit discussion, the education you provided, and the patient's understanding; that is good care and good medicolegal practice. You are not going out on a limb by using an FDA-approved antidepressant for its approved indication in a patient who has failed the alternatives.
Having rules doesn't make phenelzine dangerous. Following them is why it is safe, and the rules are a short, teachable list, not a lifelong lab-monitoring burden. You already counsel patients about metabolic monitoring on antipsychotics and about NSAIDs on lithium. With phenelzine, that attention takes the form of a diet handout, a drug-clearance rule, and a partnership with an educated patient. In return, the patients who need it most get one of the most effective antidepressants in psychiatry.
Part 1: Indications
FDA-Approved Uses
- Depression clinically characterized as "atypical," "nonendogenous," or "neurotic" (the label's wording), often with mixed anxiety and phobic or hypochondriacal features.
Phenelzine has long been positioned as an antidepressant with real anxiolytic properties, more so than its more stimulating cousin tranylcypromine, and that shapes where it works best clinically.
The Evidence-Based Clinical Uses
Atypical depression
The atypical phenotype (increased appetite and weight, increased sleep, leaden paralysis where limbs feel weighed down, and marked interpersonal rejection sensitivity) is where MAOIs earned their reputation. Meta-analysis found MAOIs more effective than tricyclics for atypical depression. (More recent data do not show a clear advantage over SSRIs on average, but many clinicians still prefer MAOIs here, and individual patients who fail SSRIs respond.) If a patient has the atypical picture and hasn't responded to first-line agents, phenelzine belongs on the list.
Treatment-resistant depression
MAOIs sit at Stage 4 of the classic TRD algorithm because they can rescue patients nothing else has helped. The comparable agent tranylcypromine produced a ~50% response rate in patients who had failed two or more tricyclics, which is high for a population defined by prior failure. Phenelzine is the best-studied MAOI for atypical depression and, historically, among the most affordable. An MAOI trial is a real, distinct pharmacologic option, not a gesture of last resort, and most "treatment-resistant" patients have never had one.
Social anxiety disorder
Phenelzine shows a large effect size across five RCTs (454 patients total), compared with the small effect seen with SSRIs. It can also augment CBT/psychotherapy. For severe, generalized, disabling social anxiety that hasn't yielded to SSRIs, phenelzine is one of the most effective drugs available. This is a standout indication, and an underused one.
Panic disorder
Effective, and particularly useful when panic is comorbid with social anxiety, a common combination.
Dysthymic disorder (persistent depressive disorder)
Demonstrated efficacy.
Off-label, pilot-level evidence
PTSD and bulimia nervosa have small supporting studies. (Use caution in eating disorders where purging or dietary chaos undermines tyramine control.)
The best phenelzine candidate is often the patient in front of you who has "failed everything," but look closer. Failed what, and at what dose? An MAOI is the classic example of a drug that works in "treatment-resistant" patients specifically because it has a mechanism different from everything that came before it. The resistance is often to a class, not to all pharmacology.
Who Phenelzine Is Especially Good For
- Anxious, agitated, or hyperaroused depressed patients: phenelzine's sedating, anxiolytic profile is therapeutic here (in contrast to the more activating tranylcypromine).
- Patients with prominent atypical features or clear rejection sensitivity.
- Severe social anxiety with or without comorbid depression or panic.
Who Is a Poor Candidate
- Anyone who cannot or will not follow the dietary and drug restrictions. This is the central gatekeeping question. It includes patients with active stimulant use disorder, chaotic living situations that preclude dietary control, or cognitive limitations that prevent reliable adherence.
- Patients on multiple serotonergic agents who cannot safely wash out.
- Patients at high baseline risk for hypertensive or cardiovascular catastrophe (see contraindications).
- Pheochromocytoma: an absolute contraindication. The Nardil label also contraindicates hypersensitivity to the drug or its ingredients, congestive heart failure, severe renal impairment or renal disease, and a history of liver disease or abnormal liver function tests.
Borderline personality disorder is a judgment call. MAOIs are arguably among the more effective antidepressants in this population, but their use is controversial: impulsivity, dietary unpredictability, and overdose risk all cut against them. Weigh candidacy on the individual's demonstrated reliability, not the diagnosis alone.
Part 2: Before You Start: Workup and Candidacy
Phenelzine, unlike lithium or the tricyclics, does not require serum-level monitoring, routine bloodwork, or a baseline ECG in an otherwise healthy adult. The workup is clinical, and it is heavily weighted toward interaction screening and readiness assessment.
The Candidacy Checklist
| Domain | What to establish |
|---|---|
| Baseline blood pressure, sitting and standing | The one measurement that matters most; you will track orthostasis against it |
| Baseline heart rate | Sitting and standing |
| Cardiovascular history | Uncontrolled hypertension, significant CV disease, cerebrovascular disease raise risk |
| Complete medication reconciliation | Every prescription, OTC, and supplement; hunt for serotonergic agents and sympathomimetics |
| Washout status | Confirm any prior serotonergic antidepressant has been cleared (see Part 7) |
| Renal and hepatic function | Impairment promotes accumulation and orthostasis; consider labs if clinically indicated |
| Diet and adherence assessment | Can this patient realistically follow the restrictions? |
| Substance use | Active stimulant/cocaine/MDMA use is a hard barrier (hypertensive risk); heavy alcohol complicates things |
| Pregnancy status / plans | In any patient of childbearing potential |
With no routine labs, no drug level, and no mandatory ECG in a healthy adult, the workup comes to a conversation and a blood-pressure cuff. Order labs (renal, hepatic) selectively when the history warrants.
The Washout: Do Not Skip This
The most dangerous moment in the life of an MAOI prescription is the switch into or out of it. Before you start phenelzine, any serotonergic antidepressant must be fully cleared. Get this timing right before you write the first tablet (full details in Part 7):
- Most SSRIs/SNRIs: taper, then wait at least 14 days (≥5 half-lives of the prior drug).
- Fluoxetine: wait at least 5 weeks because of its long half-life.
- Benzodiazepines can bridge the drug-free gap to relieve symptoms.
Part 3: How to Start and Dose
Older adultsFDA labelIn general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range.In practiceStart at 15 mg a day and titrate more slowly; the target is unchanged.
When to take itFDA labelThree times a day: one tablet (15 mg) per dose as the usual start.In practiceDivided doses are preferable to once daily; evening dosing is often well tolerated.
With barbituratesFDA labelBarbiturates should be given at a reduced dose with Nardil.
Stopping and switchingFDA labelAfter maximum benefit, dosage should be reduced slowly over several weeks.In practiceTaper slowly. Wait at least 14 days after the last dose before a serotonergic drug.
Formulation
Phenelzine comes as a 15 mg tablet (the only strength in the Nardil label). Tranylcypromine comes as 10 mg tablets. The label lists no long-acting or liquid form; dosing is done in 15 mg increments.
Dosing by Indication
- Depression of the atypical, nonendogenous or neurotic type (FDA-approved): the label starts at 15 mg TID and increases "at a fairly rapid pace" to 60 mg/day as tolerated, then up to 90 mg/day where needed. In practice many prescribers start lower (15 mg once daily) and titrate up over 1–2 weeks to reduce early orthostasis. Where you end up (60–90 mg/day) matters more than the exact ramp.
- Panic disorder (off-label): 15 mg at bedtime, titrated to 15 mg TID over about a week, then upward as needed.
- Social anxiety disorder (off-label): 15 mg/day increased toward 60 mg/day over ~2 weeks; mean effective dose in trials was ~30 mg BID, with up to 90 mg/day for insufficient response.
Starting Dose and Titration
- Label start: 15 mg PO three times daily. A common real-world alternative is 15 mg once daily (morning or midday), building up to divided dosing over the first week.
- Titrate toward 60 mg/day at a fairly rapid pace as tolerated, watching orthostatic blood pressure at each step; go to 90 mg/day if response is incomplete.
- A reasonable gentle schedule: 15 mg/day → 30 mg/day → 45 mg/day over the first ~1–2 weeks, then continue upward toward the therapeutic target based on response and tolerability.
- Slow the titration if orthostasis emerges: postural hypotension is the rate-limiting side effect and the main reason to go slowly.
Target Dose: Get to a Real Dose
- Target ≈ 1 mg/kg/day: for most adults this lands at 60–90 mg/day, commonly ~75 mg/day. The label says up to 90 mg/day may be necessary for sufficient MAO inhibition.
- Do not stop short. The label says to increase the dose to at least 60 mg a day at a fairly rapid pace, and that many patients do not respond until 60 mg has been continued for at least 4 weeks.
- Response is dose-dependent: if a patient tolerates the drug but hasn't responded at a modest dose, pushing higher (within the therapeutic range) is often what produces the response.
- Maintenance: once remission is stable, reduce to the lowest dose that holds it, often 15 mg/day or every other day.
"One milligram per kilogram." If your patient weighs 75 kg and you're sitting at 45 mg wondering why phenelzine "isn't working," check the dose against the target: the label says to reach at least 60 mg a day, and 1 mg/kg is about 75 mg here.
Dosing Schedule
- Divided dosing (BID or TID) is preferable to once daily: splitting the dose meaningfully reduces orthostatic hypotension, the dominant tolerability problem.
- Because phenelzine tends to be sedating rather than activating, evening dosing is often well tolerated and can even help with sleep. With the more stimulating tranylcypromine, by contrast, you avoid late-day dosing to prevent insomnia. Individualize: if a given patient finds phenelzine activating, shift the load earlier.
Dose Adjustments and Special Populations
- Hepatic impairment: contraindicated in patients with liver disease or abnormal liver function tests, since phenelzine is hepatically metabolized and has been associated with hepatotoxicity.
- Renal impairment: use cautiously in mild-to-moderate impairment (risk of accumulation); avoid in severe impairment. Dialyzability is not established.
- Geriatric: start at 15 mg/day and titrate slowly; older patients are markedly more susceptible to orthostatic hypotension and falls. The therapeutic target is unchanged, but the ramp should be gentler.
- Pediatric: Nardil is not approved for use in treating any indication in the pediatric population, and safety and effectiveness have not been established (label).
- Pregnancy/lactation: generally avoided; MAOIs are rarely first-line in pregnancy given hypertensive-crisis risk and limited data. No dose adjustment is defined. The decision is whether to use it at all, made case by case.
Stopping and Switching
- Discontinuation: taper rather than stop abruptly; the Nardil label describes an uncommon withdrawal syndrome after abrupt withdrawal, beginning 24 to 72 hours after the last dose and ranging from vivid nightmares with agitation to frank psychosis and convulsions.
- MAOI washout when switching: allow at least 14 days after stopping phenelzine before starting another MAOI or a serotonergic agent, to let MAO enzyme regenerate. Going the other way, allow the standard washout of the prior drug first: at least 14 days for most serotonergic antidepressants, and at least 5 weeks after fluoxetine because of its long half-life.
How Long Until It Works
As with other antidepressants, expect a few weeks before a meaningful response, sometimes longer at full dose. The enzyme inhibition is effectively complete early on, but the downstream clinical effect builds over weeks. Do not declare failure until the patient has had an adequate dose for an adequate duration.
Part 4: Monitoring
Monitoring phenelzine is the reverse of monitoring lithium: there are no routine labs, no serum drug level, and no mandatory ECG. MAO inhibition is not something you titrate against a blood test. What you monitor is clinical: blood pressure, tolerability, and, above all, ongoing adherence to the interaction rules.
The Monitoring Schedule
| Timepoint | What to do |
|---|---|
| Baseline | BP and HR, sitting and standing; med reconciliation; diet counseling |
| First 2–4 weeks (titration) | Frequent visits, often weekly, to check orthostatic BP, tolerability, and early response |
| Each visit | Recheck BP (sitting → standing after 2–3 min); reinforce diet and drug rules; screen for new medications from other providers |
| Ongoing / stable | Routine follow-up as for any antidepressant; re-counsel on interactions periodically, this is not a one-time conversation |
What You're Watching For
- Orthostatic hypotension: the most common problematic effect; track standing BP and symptoms.
- Insomnia or over-sedation: adjust dose timing.
- Weight change and sexual dysfunction: ask directly; patients underreport both.
- New medications from other prescribers: the recurring danger. Ask at every visit: "Has any other doctor, dentist, or pharmacist given you anything new?"
- Dietary adherence: check in; drift is common once patients feel well.
Teach the patient to check their own blood pressure at home: seated, then standing after 2–3 minutes, recording both numbers and heart rate. It helps you titrate against real-world orthostasis, and it makes the patient an active participant in their own safety. A patient who owns a cuff and knows their numbers is safer.
Part 5: Side Effects and How to Manage Them
Phenelzine is the "high side effect MAOI": more sedation, more weight gain, and prominent sexual dysfunction compared with tranylcypromine. As with any powerful drug, most of these are manageable and most are dose-related, and you have to get ahead of them, because tolerability, not efficacy, is what drives patients off the medication. For context, MAOI side effects across the class are comparable to SSRIs in overall frequency and severity; the trade-off is more hypotension but fewer GI problems.
Orthostatic Hypotension (the dominant problem)
The most common and most limiting side effect. It causes dizziness, lightheadedness on standing, and, especially in the elderly, falls, syncope, and confusion.
Management, in order:
- Titrate slowly and use divided dosing (BID/TID) rather than a single daily dose: this alone prevents much of it.
- Increase fluid intake: aim for roughly 8 glasses of water a day.
- Liberalize salt (if no cardiac/renal contraindication) and consider compression/support stockings.
- Reduce or remove concurrent antihypertensives where clinically appropriate: the patient is often over-treated for BP once the MAOI is on board.
- Reduce the phenelzine dose if orthostasis is intolerable at the current level.
- Refractory cases: fludrocortisone (a mineralocorticoid that expands volume), titrated carefully; monitor for supine hypertension, edema, and hypokalemia.
It seems backward that the drug that can cause a hypertensive crisis with tyramine causes low blood pressure as its routine side effect. The two are not contradictory: the crisis is an acute, food/drug-triggered surge, while the orthostasis is the chronic baseline effect. Manage the orthostasis as a day-to-day comfort-and-safety issue, and keep the tyramine rules as a separate, event-driven safety system.
Sedation
Phenelzine is quite sedating, more so than tranylcypromine (though it causes less insomnia than Parnate).
Management:
- Often an asset: dose in the evening so the sedation aids sleep. It can also be a real help in agitated or anxious patients.
- If daytime sedation is a problem, shift more of the dose to the evening.
- For persistent, impairing daytime sleepiness, a cautiously monitored psychostimulant (methylphenidate, dextroamphetamine) has been used by experts with MAOIs without hypertensive crisis, but it is an off-label expert maneuver (the Nardil label contraindicates it) that needs close BP monitoring, and it is not routine.
Insomnia / Activation
Less common with phenelzine than with tranylcypromine, but it happens.
Management:
- Shift dosing earlier in the day.
- Benzodiazepines are safe with MAOIs and can be used for sleep. Trazodone has been used successfully for MAOI-associated insomnia by experienced clinicians (technically off-label/contraindicated on paper, but a long track record in expert hands at low doses).
- Do NOT use doxepin/Silenor as a hypnotic: it is not safe with MAOIs.
Weight Gain
Significant with phenelzine, more than tranylcypromine, which causes the least weight gain of the older MAOIs.
Management:
- Counsel on diet and activity up front, before it accumulates.
- Monitor weight at visits and intervene early.
- If weight gain is the dealbreaker, tranylcypromine (less weight gain) or another strategy may be considered, but don't abandon a working antidepressant lightly.
Sexual Dysfunction
Common with phenelzine (reduced libido, delayed orgasm, anorgasmia) and a frequent, under-reported reason for covert non-adherence.
Management:
- Ask directly: patients rarely volunteer it.
- Options include dose reduction and cautious adjunctive strategies used by experienced prescribers (e.g., a monitored psychostimulant, which the Nardil label contraindicates). PDE5 inhibitors (sildenafil, tadalafil) are commonly used for the erectile component and are not MAOI-contraindicated.
- Weigh it against the fact that this may be the only drug the patient responds to, and make it a frank shared decision.
Other Effects
- Anticholinergic-type effects (dry mouth, constipation) and peripheral edema can occur.
- Hepatotoxicity is a recognized, uncommon risk of the hydrazine MAOIs: be alert to symptoms of liver injury and investigate if they arise.
- Vitamin B6 (pyridoxine) depletion can occur with phenelzine and may manifest as numbness/paresthesias; B6 supplementation treats it.
- Rare: a switch into mania/hypomania in vulnerable (bipolar-spectrum) patients: screen for bipolarity before starting, as with any antidepressant.
Part 6: The Two Emergencies: Hypertensive Crisis and Serotonin Syndrome
Beyond its boxed warning on antidepressant suicidality, phenelzine's serious risks are not chronic organ toxicity: they are two acute, largely preventable emergencies driven by interactions. Know both cold.
- Suicidality and antidepressant drugs. Antidepressants increased the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder and other psychiatric disorders. Short-term studies did not show an increase in risk in adults beyond age 24, and showed a reduction in risk in adults aged 65 and older. Monitor patients of all ages who start antidepressant therapy for clinical worsening, suicidality, and unusual changes in behavior, and tell families and caregivers to observe closely and stay in touch with the prescriber. Nardil is not approved for use in pediatric patients.
Emergency 1: Hypertensive Crisis (the "cheese reaction")
Mechanism. MAO in the gut wall normally breaks down dietary tyramine, a vasoactive amine. Inhibit that enzyme, and ingested tyramine floods the circulation, displacing norepinephrine from sympathetic nerve terminals. The result is an abrupt, sometimes severe rise in blood pressure. The same mechanism drives crises with sympathomimetics (decongestants, stimulants).
Presentation. Sudden, severe, pounding headache. Patients classically describe a feeling that the head will "split," often with a racing heart, sweating, nausea, neck stiffness, and photophobia. In severe cases: hypertensive encephalopathy, intracranial hemorrhage.
Patient-facing rule. If a sudden, severe headache develops, the patient should hold the next dose, check blood pressure if a cuff is at hand, and get evaluated promptly. The Nardil label says to discontinue therapy immediately for palpitations or frequent headaches. Sustained readings of 180 systolic or 110 diastolic and above define hypertensive urgency, and signs of end-organ damage make it an emergency. Have the plan in writing.
Acute management:
- Do not give or prescribe immediate-release nifedipine for the patient to chew. It can drop blood pressure faster than the brain and heart tolerate, which can cause stroke or sudden permanent blindness (Gillman 2020). The 2022 Prescriber's Guide to Classic MAO Inhibitors (Van den Eynde et al.) calls sublingual nifedipine strongly contraindicated, and the old carry-it-with-you rescue is retired.
- Most episodes need no drug treatment. After excessive tyramine, blood pressure typically peaks within about 2 hours and settles on its own, so aggressive lowering risks overshooting into hypotension. The first step the experts favor is calm, a benzodiazepine and blood-pressure monitoring.
- Send the patient for emergency evaluation when readings stay high or there are signs of end-organ damage. The Nardil label recommends phentolamine (5 mg IV, given slowly to avoid excessive hypotension), and the 2022 guide suggests an infusion because its half-life is only about 19 minutes and it can be titrated. The emergency physician treats with the short duration of the reaction in mind.
- The older suggestion to prescribe labetalol capsules for home use cannot be supported (Van den Eynde et al. 2022).
- Many patients who reach an ER waiting room find the BP has begun normalizing on its own before intervention. Not every reaction requires dramatic treatment, but every suspected reaction requires evaluation.
The crisis is dramatic but rare in educated patients, and the risk is tightly tied to specific foods and drugs, not to "everything." Tranylcypromine carries a somewhat higher tyramine-reaction risk than phenelzine (its amphetamine-like structure), but the counseling is the same for both. If you do see a reaction, it is far more likely to come from a hidden decongestant than from a meal.
Emergency 2: Serotonin Syndrome
This is the one to fear most, because it can be lethal and because it can arrive from an outside prescriber. MAOIs raise the risk of serotonin syndrome more than any other drug class.
Mechanism. MAOI + a serotonergic agent → uncontrolled excess of synaptic serotonin.
Presentation (a triad):
- Neuromuscular: clonus (especially inducible/ocular), hyperreflexia, tremor, rigidity.
- Autonomic: hyperthermia, tachycardia, hypertension, diaphoresis, mydriasis.
- Mental status: agitation, confusion, delirium.
Management: stop the offending agent, supportive care and cooling, benzodiazepines, and cyproheptadine as a serotonin antagonist; severe cases require ICU-level care. Serotonin syndrome is a medical emergency and belongs in the ED.
Prevention is everything: rigorous washout discipline, patient education, MAOI identification, and the absolute prohibitions in Part 7.
The Withdrawal Syndrome (uncommon but real)
Abruptly stopping phenelzine can uncommonly precipitate a withdrawal syndrome. The Nardil label says it generally begins 24 to 72 hours after the last dose, ranges from vivid nightmares with agitation to frank psychosis and convulsions, and generally responds to restarting low-dose phenelzine followed by cautious downward titration. Prevent it by tapering slowly rather than stopping cold (see Part 9).
Part 7: Drug and Food Interactions
Safe prescribing of phenelzine rests on this section. Learn it well enough to teach it.
Food: The Tyramine Diet
The list is shorter than you think. Most of the terrifying dietary lists in circulation predate modern tyramine measurement, and current, accurately quantified data show that the foods that are actually dangerous are a short list of aged, fermented, and spoiled items, not a blanket ban on cheese and wine.
- Aged/matured cheeses (cheddar, blue, aged gouda, parmesan, etc.)
- Cured, aged, or fermented meats (dry sausage, salami, pepperoni, aged/pickled/smoked fish)
- Tap/draft beer and unpasteurized/home-brewed beers
- Fermented soy products in quantity (soy sauce, miso, fermented tofu)
- Sauerkraut and other fermented vegetables
- Fava (broad) beans, and their pods
- Marmite/concentrated yeast extracts
- Any aged, spoiled, or improperly stored protein: freshness matters as much as food type
- Fresh cheeses: mozzarella (fresh pizza with mozzarella is safe), cream cheese, cottage cheese, ricotta
- Fresh meat, poultry, and fish (properly stored)
- Bottled/canned beer and wine in moderation (expert opinion; the Nardil label lists beer and wine among beverages to avoid and says not to combine it with alcohol)
Teach the principle, not just the list: aged, fermented, spoiled, or improperly stored = risk; fresh = safe. A patient who understands the "why" (tyramine builds up as proteins age and ferment) makes better real-world decisions in a restaurant than one who has memorized a list they'll inevitably encounter exceptions to. The much-repeated fear that patients on MAOIs can "never eat pizza" is simply wrong for fresh-mozzarella pizza.
Drugs That Can Cause Hypertensive Crisis (sympathomimetics)
- OTC decongestants: pseudoephedrine, phenylephrine: the single most common real-world culprit; hidden in countless cold/flu products.
- Stimulants and drugs of abuse: cocaine, illicit amphetamines, MDMA.
- The Nardil label contraindicates sympathomimetic drugs, including prescribed amphetamines and methylphenidate, and related compounds such as methyldopa and L-dopa. Some experts use a stimulant with careful monitoring, off-label, but it is a hazard in uncontrolled hands.
- Buspirone: contraindicated on the Nardil label (cases of elevated blood pressure in patients on MAOIs). The label also asks for at least 14 days between stopping Nardil and starting it.
Drugs That Can Cause Serotonin Syndrome: Absolute or Near-Absolute Avoid
- All serotonergic antidepressants: SSRIs, SNRIs (venlafaxine, duloxetine), clomipramine, vortioxetine.
- Meperidine (Demerol): a classic, dangerous, often-overlooked culprit; flag it for any surgical/anesthetic context. Tramadol and other serotonergic opioids carry similar risk.
- Dextromethorphan: the "DM" in OTC cough/cold syrups.
- L-tryptophan and St. John's wort (supplements).
- Ziprasidone: its own label contraindicates it in patients taking an MAOI, or within 14 days of stopping one, because of serotonin syndrome risk.
- Doxepin/Silenor as a hypnotic.
- Triptans and carbamazepine: use only with caution/monitoring (real but lower/variable risk); many clinicians simply avoid them.
Anesthesia and Surgery
Any surgery, dental procedure, or anesthesia requires advance coordination: meperidine and certain sympathomimetic/vasopressor agents are hazardous. The patient's MAOI status must be communicated to the surgical and anesthesia teams well ahead of time. This is exactly what the MedicAlert identification is for. The Nardil label says patients should not undergo elective surgery requiring general anesthesia, should not be given cocaine or local anesthesia containing sympathomimetic vasoconstrictors, and should stop Nardil at least 10 days before elective surgery.
Agents Used in Expert Practice (Some Contraindicated on the Label)
Decades of expert experience have identified agents that some prescribers combine with MAOIs. The Nardil label contraindicates bupropion and prescribed stimulants, so those two are off-label specialist choices:
- Bupropion (not serotonergic), but contraindicated on the Nardil label, which asks for at least 14 days between stopping an MAOI and starting bupropion.
- Mirtazapine (used cautiously by experts).
- Certain tricyclics: trimipramine and amitriptyline (avoid the serotonergic clomipramine); combinations require care and expertise.
- Trazodone: low-dose, for sleep; officially contraindicated but used safely off-label in expert hands (one series treated ~80 patients uneventfully).
- Benzodiazepines: safe; useful for anxiety, insomnia, and bridging washouts.
- Lithium: the augmentation agent with the most evidence behind it.
- Second-generation antipsychotics: combinable except ziprasidone.
- Psychostimulants: contraindicated on the label; usable by experts with BP monitoring.
Do NOT augment with highly serotonergic agents (SSRIs, SNRIs, clomipramine).
Washout Periods: Switching Into and Out of Phenelzine
Starting phenelzine (clear the old drug first)
| Prior agent | Washout before starting phenelzine |
|---|---|
| Most SSRIs/SNRIs | Taper, then wait at least 14 days (≥5 half-lives of the prior agent) |
| Fluoxetine | Wait at least 5 weeks (long half-life; can be stopped abruptly, but the wait is long) |
| Vortioxetine | At least 21 days after the last dose (Trintellix label) |
| Bridging | Bridge the gap with a benzodiazepine to cover symptoms during the drug-free interval |
Stopping phenelzine (before starting a serotonergic drug)
| Step | What to do |
|---|---|
| Taper | Taper the phenelzine slowly; the label reports a withdrawal syndrome after abrupt withdrawal |
| The "2-week rule" | Then wait ~2 weeks after the last dose before starting any serotonergic antidepressant and before lifting dietary/drug restrictions |
| Why | Enzyme regeneration takes about two weeks because inhibition is irreversible; the body must synthesize new MAO |
The "wait 2 weeks after stopping" rule is not optional, and the two weeks are pharmacology, not conservative padding. Because phenelzine inhibits MAO irreversibly, the drug being gone from the bloodstream does not mean the enzyme is back. The patient remains functionally "on an MAOI" for interaction purposes until new enzyme is synthesized, roughly two weeks later.
Part 8: Special Populations
Pregnancy
- Limited safety data: phenelzine is an old drug that was never well studied in pregnancy, and it is generally avoided when safer, better-characterized alternatives exist.
- Additional concern: the interaction/hypertensive-crisis profile complicates obstetric care, and certain agents used peripartum can be hazardous.
- If a patient with severe, treatment-refractory illness is already stable on phenelzine, the decision is an individualized risk/benefit discussion (untreated severe depression carries its own substantial fetal and maternal risk), ideally co-managed with maternal-fetal medicine.
Lactation
- Transfer into breast milk is not well characterized. Caution is warranted; a careful benefit/risk assessment and coordination with pediatrics are needed if a mother wishes to continue.
Elderly
- Orthostatic hypotension is the dominant concern: it drives falls, fractures, syncope, cardiac/cerebral ischemia, and confusion.
- Start lower, titrate more slowly, monitor BP closely (in office and at home).
- Polypharmacy multiplies interaction risk: reconcile medications line by line and re-screen at every visit.
- Consider whether a better-studied agent in the elderly would serve, but MAOIs remain a legitimate option for the older patient whose depression is truly refractory.
Renal Impairment
- Contraindicated in severe renal impairment or renal disease (label). In mild-to-moderate impairment the concerns are accumulation and worse orthostatic hypotension, so reduce the dose and monitor closely.
Hepatic Impairment
- Contraindicated in a history of liver disease or abnormal liver function tests (label). Phenelzine is hepatically metabolized and carries an uncommon hepatotoxic potential as a hydrazine, so the label bars its use in these patients rather than calling for a lower dose.
Children and Adolescents
- Not typically used. The label says Nardil is not approved for use in treating any indication in the pediatric population and that safety and effectiveness have not been established; the dietary/drug-adherence demands are also a poor fit for most of this population. Reserve for specialist use in exceptional circumstances.
Part 9: Discontinuation
Phenelzine should be tapered, not stopped abruptly.
Abrupt discontinuation can uncommonly precipitate a withdrawal syndrome, which the Nardil label describes as ranging from vivid nightmares with agitation to frank psychosis and convulsions. Taper slowly rather than stopping cold; for the dose reduction after maximum benefit, the label says to reduce slowly over several weeks.
- Then observe the "2-week rule": after the last dose, wait ~2 weeks before starting a serotonergic antidepressant or relaxing the dietary and drug restrictions, because irreversible MAO inhibition persists until new enzyme is synthesized. The patient is still, functionally, on an MAOI during that window.
- As with any effective antidepressant, weigh discontinuation against relapse risk; don't stop a drug that finally worked in a treatment-resistant patient without a compelling reason and a clear plan.
The two-week tail after stopping is where preventable serotonin-syndrome deaths happen: a patient stops phenelzine on Monday and a covering clinician starts an SSRI on Friday. Write the stop date and the "safe to start a serotonergic drug" date directly into the chart, and tell the patient both numbers.
Part 10: Phenelzine vs the Alternatives
Within the MAOI Class
| vs Agent | The comparison |
|---|---|
| Tranylcypromine (Parnate) | Parnate is the more stimulating/dopaminergic MAOI: less sedation, less weight gain, but more insomnia and a somewhat higher tyramine-reaction risk (amphetamine-like structure). Phenelzine is the more sedating, anxiolytic MAOI: more weight gain and sexual dysfunction, but calmer, with less insomnia. Choose phenelzine for anxious/agitated patients; choose tranylcypromine for anergic/apathetic/lethargic ones. The first head-to-head (Birkenhäger et al., 2004) confirmed Parnate is less sedating but causes more insomnia than Nardil. |
| Isocarboxazid (Marplan) | Reapproved in 1998 (max 60 mg/day). Efficacy is roughly equal to phenelzine and tranylcypromine, and some evidence suggests it is better tolerated than phenelzine, but it is the least studied and can be more expensive. A reasonable choice if cost/availability favors it or the patient has a prior good response. |
| Selegiline patch (Emsam) | The transdermal patch has a much cleaner side-effect profile (minimal weight gain, sexual dysfunction, and fatigue), and at the 6 mg dose requires no dietary restrictions, a genuine advantage for diet-noncompliant patients or those intolerant of older MAOIs. The catch: it lacks the efficacy data in TRD and atypical depression that the oral MAOIs have. If you are specifically treating refractory or atypical depression, the oral agents (including phenelzine) have the evidence; if tolerability and dietary freedom are paramount, the patch is attractive. |
| Moclobemide | A reversible MAO-A inhibitor with no meaningful dietary restrictions, but not available in the US, and reportedly less effective than the irreversible non-selective MAOIs. |
Against the Broader Antidepressant Field
- vs SSRIs/SNRIs: Overall side-effect burden is comparable (more hypotension, fewer GI effects), but SSRIs win decisively on ease of use: no diet, minimal interaction management, no washout choreography. That convenience is why phenelzine sits later in the algorithm. In the specific populations where phenelzine excels (atypical depression, refractory depression, severe social anxiety), though, it can deliver responses SSRIs do not.
- Where it fits: Phenelzine is not a first-line drug and shouldn't be. For patients who have exhausted the easy options it is a high-value later-line drug, and one of the most effective tools remaining.
Why is it underused? No marketing budget (a cheap generic), an outdated reputation for danger, unfamiliarity among clinicians trained after the SSRI era, and the real (but manageable) hassle of dietary and interaction counseling. Only about 2% of psychiatrists prescribe MAOIs with any regularity. None of these are clinical reasons to withhold an effective drug from a patient who needs it.
Mechanism
Phenelzine is a non-selective, irreversible inhibitor of monoamine oxidase, a member of the hydrazine chemical family. It inhibits both isoenzymes:
- MAO-A metabolizes serotonin, norepinephrine, epinephrine, and dopamine: inhibiting it raises synaptic levels of all four, which underlies the antidepressant and anxiolytic effect.
- MAO-B primarily metabolizes dopamine and phenylethylamine. Dietary tyramine, by contrast, is broken down chiefly by MAO-A in the gut wall, which is why selective MAO-B inhibitors do not trigger the cheese reaction. Phenelzine produces the hypertensive-crisis vulnerability because, as a non-selective inhibitor, it also knocks out this MAO-A-mediated intestinal tyramine defense.
Because the inhibition is irreversible ("suicide" inhibition: phenelzine permanently inactivates the enzyme), the effect outlasts the drug: normal MAO activity returns only as the body synthesizes new enzyme over roughly two weeks. That one pharmacologic fact explains three clinical rules: why the drug keeps working despite a short plasma half-life, why you must wait two weeks after stopping before a serotonergic drug or a relaxed diet, and why the dietary restrictions cannot be "skipped for a day."
The Bedside Cheat Sheet
Starting
- 15 mg tablet. Label start: 15 mg three times a day; a gentler ramp (15 mg/day, then 30, then 45 mg over the first ~1–2 weeks) is the more cautious practice, with orthostatic BP checked at each step
- Target ≈ 1 mg/kg/day → usually 60–90 mg/day. Do NOT stop short of 60 mg a day (label: at least 60 mg, up to 90 mg if needed)
- Divided dosing (BID/TID) cuts orthostatic hypotension. Phenelzine is sedating → evening dosing often fine
- Workup: BP sitting + standing, med reconciliation, washout of prior serotonergic drug. No routine labs, no level, no ECG in a healthy adult
Monitoring
- Boxed warning: antidepressant suicidality in children, adolescents and young adults; watch patients of all ages for worsening and unusual changes in behavior
- Frequent visits in the first weeks; BP (sitting → standing) at each titration step
- Re-counsel on diet + drug rules repeatedly; ask about new meds from other providers every visit
Side effects
- Orthostasis (dominant): slow titration, divided dosing, fluids/salt, stockings, cut antihypertensives; refractory → fludrocortisone
- Sedation: often an asset (PM dosing). Weight gain + sexual dysfunction: counsel early, ask directly
- B6 depletion: supplement pyridoxine for paresthesias
The two emergencies
- Hypertensive crisis (tyramine/sympathomimetics): splitting headache → hold the dose, check BP, get evaluated. Benzodiazepine + BP monitoring first; no nifedipine to carry; any IV drug is an ED decision. Cause is usually a hidden decongestant, not a meal
- Serotonin syndrome (any serotonergic drug): clonus/hyperreflexia + autonomic instability + AMS → ED; cyproheptadine
Never combine with
- SSRIs/SNRIs, clomipramine, vortioxetine, meperidine/tramadol, dextromethorphan, decongestants (pseudoephedrine/phenylephrine), ziprasidone, doxepin/Silenor, St. John's wort, L-tryptophan, cocaine/amphetamines/MDMA; also contraindicated on the label: buspirone, bupropion, methylphenidate
Diet (short list)
- Avoid: aged cheese, cured/fermented meats, tap beer, sauerkraut, soy sauce/miso, fava beans, yeast extract, anything spoiled
- Safe: fresh mozzarella (pizza OK), fresh meat/fish, bottled beer & wine in moderation (expert opinion; the Nardil label says avoid beer and wine). Principle: aged/fermented = risk; fresh = safe
Switching (the rules that save lives)
- Into phenelzine: wait ≥14 days off SSRIs/SNRIs; ≥5 weeks off fluoxetine
- Off phenelzine: taper slowly, then wait ~2 weeks after the last dose before any serotonergic drug or relaxed diet (irreversible inhibition: new enzyme takes ~2 weeks)
Don't forget
- Give a written diet/drug handout + action plan; consider MedicAlert ID
- Underdosing, not the diet, is the usual reason phenelzine "fails"
- Best candidates: atypical depression, TRD, severe social anxiety, anxious/agitated depression
Phenelzine asks more of the prescriber than an SSRI does: a diet handout, a drug-interaction rule, a two-week washout on each end, and an educated, engaged patient. For patients who have already failed the convenient options, it can produce a response the easy drugs often cannot, in atypical depression, in treatment-resistant depression, and in severe social anxiety. The interactions that frighten clinicians are real, but they are finite and teachable, and decades of careful use show that catastrophe is rare in the educated patient. Prescribed with respect for its two emergencies and pushed to a properly therapeutic dose, phenelzine is one of the most effective antidepressants we have, not a dangerous relic, and it is waiting for the small number of patients who need exactly what it does.